HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gross, J. L. Articles by Zelmanovitz, T. Search for Related Content PubMed PubMed Citation Articles by Gross, J. L. Articles by Zelmanovitz, T. Social Bookmarking                What's this?

Diabetic Nephropathy: Diagnosis, Prevention, and Treatment

From the Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Address correspondence and reprint requests to Jorge L. Gross, Serviço de Endocrinologia do Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Prédio 12, 4° andar, 90035-003, Porto Alegre, RS, Brazil. E-mail: jorgegross{at}terra.com.br

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects 40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other renal diseases. Diabetic nephropathy is categorized into stages: microalbuminuria (UAE >20 µg/min and 199 µg/min) and macroalbuminuria (UAE 200 µg/min). Hyperglycemia, increased blood pressure levels, and genetic predisposition are the main risk factors for the development of diabetic nephropathy. Elevated serum lipids, smoking habits, and the amount and origin of dietary protein also seem to play a role as risk factors. Screening for microalbuminuria should be performed yearly, starting 5 years after diagnosis in type 1 diabetes or earlier in the presence of puberty or poor metabolic control. In patients with type 2 diabetes, screening should be performed at diagnosis and yearly thereafter. Patients with micro- and macroalbuminuria should undergo an evaluation regarding the presence of comorbid associations, especially retinopathy and macrovascular disease. Achieving the best metabolic control (A1c <7%), treating hypertension (<130/80 mmHg or <125/75 mmHg if proteinuria >1.0 g/24 h and increased serum creatinine), using drugs with blockade effect on the renin-angiotensin-aldosterone system, and treating dyslipidemia (LDL cholesterol <100 mg/dl) are effective strategies for preventing the development of microalbuminuria, in delaying the progression to more advanced stages of nephropathy and in reducing cardiovascular mortality in patients with type 1 and type 2 diabetes.

Abbreviations: ARB, angiotensin II type 1 receptor blocker • DCCT, Diabetes Control and Complications Trial • GFR, glomerular filtration rate • RAS, renin-angiotensin system • UAE, urinary albumin excretion • UKPDS, U.K. Prospective Diabetes Study

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. L. Camargo, G. M. Lara, A. E. Wendland, J. L. Gross, and M. J. de Azevedo Agreement of Different Immunoassays for Urinary Albumin Measurement Clin. Chem., May 1, 2008; 54(5): 925 - 927. [Full Text] [PDF]

				M. J. Fowler Microvascular and Macrovascular Complications of Diabetes Clin. Diabetes, April 1, 2008; 26(2): 77 - 82. [Full Text] [PDF]

				A. Juutilainen, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovascular Mortality in Middle-Aged Subjects Diabetes Care, April 1, 2008; 31(4): 714 - 719. [Abstract] [Full Text] [PDF]

				G. Wang, F. M.-M. Lai, K.-B. Lai, K.-M. Chow, B. C.-H. Kwan, P. K.-T. Li, and C.-C. Szeto Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker Eur. J. Endocrinol., March 1, 2008; 158(3): 317 - 322. [Abstract] [Full Text] [PDF]

				C. Granier, K. Makni, L. Molina, B. Jardin-Watelet, H. Ayadi, and F. Jarraya Gene and protein markers of diabetic nephropathy Nephrol. Dial. Transplant., March 1, 2008; 23(3): 792 - 799. [Full Text] [PDF]

				F. Johansson, F. Kramer, S. Barnhart, J. E. Kanter, T. Vaisar, R. D. Merrill, L. Geng, K. Oka, L. Chan, A. Chait, et al. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice PNAS, February 12, 2008; 105(6): 2082 - 2087. [Abstract] [Full Text] [PDF]

				P. Weber Nutritional Challenges of a Dual Diagnosis: Chronic Kidney Disease and Diabetes Diabetes Spectr, January 1, 2008; 21(1): 26 - 29. [Abstract] [Full Text] [PDF]

				S. Puppala, R. Arya, F. Thameem, N. H. Arar, K. Bhandari, D. M. Lehman, J. Schneider, S. Fowler, V. S. Farook, V. P. Diego, et al. Genotype by Diabetes Interaction Effects on the Detection of Linkage of Glomerular Filtration Rate to a Region on Chromosome 2q in Mexican Americans Diabetes, November 1, 2007; 56(11): 2818 - 2828. [Abstract] [Full Text] [PDF]

				E. G. Camargo, L. S. Weinert, J. Lavinsky, J. L. Gross, and S. P. Silveiro The Effect of Aspirin on the Antiproteinuric Properties of Enalapril in Microalbuminuric Type 2 Diabetic Patients: A randomized, double-blind, placebo-controlled study Diabetes Care, July 1, 2007; 30(7): e66 - e66. [Full Text] [PDF]

				M. R. Weir Microalbuminuria and Cardiovascular Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 581 - 590. [Abstract] [Full Text] [PDF]

				Protein Restriction for Renal Disease DOC News, December 1, 2006; 3(12): 4 - 4. [Full Text]

				J. Soma, K. Sato, H. Saito, and Y. Tsuchiya Effect of tranilast in early-stage diabetic nephropathy Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2795 - 2799. [Abstract] [Full Text] [PDF]

				S. S. Ossman Diabetic Nephropathy: Where We Have Been and Where We Are Going Diabetes Spectr, July 1, 2006; 19(3): 153 - 156. [Abstract] [Full Text] [PDF]

				P. P. Dobesh Managing hypertension in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1140 - 1149. [Abstract] [Full Text] [PDF]

				V. D. de Mello, T. Zelmanovitz, M. S Perassolo, M. J Azevedo, and J. L Gross Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria Am. J. Clinical Nutrition, May 1, 2006; 83(5): 1032 - 1038. [Abstract] [Full Text] [PDF]

				M. S. Farvid, M. Jalali, F. Siassi, and M. Hosseini Comparison of the Effects of Vitamins and/or Mineral Supplementation on Glomerular and Tubular Dysfunction in Type 2 Diabetes: Response to Rossing et al. Diabetes Care, March 1, 2006; 29(3): 748 - 749. [Full Text] [PDF]

				E. Galkina and K. Ley Leukocyte Recruitment and Vascular Injury in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 368 - 377. [Abstract] [Full Text] [PDF]

				M. E. Molitch, D. Rupp, and M. Carnethon Higher Levels of HDL Cholesterol Are Associated With a Decreased Likelihood of Albuminuria in Patients With Long-Standing Type 1 Diabetes Diabetes Care, January 1, 2006; 29(1): 78 - 82. [Abstract] [Full Text] [PDF]

				H. Kramer and M. E. Molitch Screening for Kidney Disease in Adults With Diabetes Diabetes Care, July 1, 2005; 28(7): 1813 - 1816. [Full Text] [PDF]

				F. Pistrosch, K. Herbrig, B. Kindel, J. Passauer, S. Fischer, and P. Gross Rosiglitazone Improves Glomerular Hyperfiltration, Renal Endothelial Dysfunction, and Microalbuminuria of Incipient Diabetic Nephropathy in Patients Diabetes, July 1, 2005; 54(7): 2206 - 2211. [Abstract] [Full Text] [PDF]